u/ewan_marchand

A hold, a request for information and a seizure are distinct administrative events. Each has its own process and deadlines, and the notice itself states which one you have.

a shoulder is not an impurity until you can resolve it

Correction: that is the claimed figure, and the measured one is the higher of the two in your own screenshot.

SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category error.

the escalation is where most of the reported trouble sits

Is this about a policy or about an individual removal?

Careful with "everyone tolerates it better". The people it did not suit stop posting, which makes this board look calmer than the drug is.

Cosigning on paperwork. The boring documents are the ones that matter when a process starts.

The evidence standard on the vendor boards requires a document, a date or a named service behind any claim about a supplier. It is what makes those threads worth reading years later.

Same view — the rules where I am changed between one year and the next and nobody announced it.

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

System suitability — repeat injections, tailing factor, plate count, RSD on area — is what tells you the instrument was fit for the measurement that day. Without it, the purity figure is unanchored.

Chain of custody is why member-funded testing is worth more than a supplied certificate: the vial tested is the vial that arrived at a member’s door.

triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part

Appetite effect for me is flat across seven days. On sema it was a wave. Same person, different molecule.

Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.

Same view — reporting the gradient is what makes a result checkable rather than merely stated.

Weekly dosing again, half-life in the same neighbourhood as sema, so a step change takes about a month to reach steady state. Judging a new step at day five is judging noise.

This is the fifth "should I go up" post today and they are all welcome — but no member here can answer it for you.

Agreed, with one qualifier: that is the mean of the top arm and the spread around it was enormous.

Came off sema and onto tirz with a two-week gap. The first month was flat and I assumed I had made a mistake. Month two it moved.

This. A shoulder that does not baseline-resolve is a question, not a quantity.

pens and vials are the same molecule, the price is the difference

Same view — reporting the gradient is what makes a result checkable rather than merely stated.

Held 7.5 for five months. Everyone kept asking when I was going to 10. The answer was never, because 7.5 was working.

area percent is relative to what the detector saw and nothing else

Appetite effect for me is flat across seven days. On sema it was a wave. Same person, different molecule.

Which week did the appetite change actually land for you?

Retitled — the original stated a discrepancy the numbers do not show.

Disagreeing with this line: that gap is ordinary variance, not a contradiction between the lab and the certificate.

This. A shoulder that does not baseline-resolve is a question, not a quantity.

UV response is not uniform across species. At 214nm you are looking at the peptide bond, which is why it is the working wavelength for this class; at 280nm you only see tryptophan, tyrosine and phenylalanine.

regain after stopping is the expected outcome, not a personal failure

Mass spectrometry answers identity. UV purity answers relative quantity under the run conditions. A document with one and not the other is answering half the question, and the half it answers should be stated.

sulphur burps are the signature complaint and they are not dangerous

Ran a blank after a high-concentration injection and found the carryover I had been calling an impurity.

stretching the interval is not the same as reducing the dose

two labs, two gradients, two honest answers

Not convinced by the proposal as worded. It would remove the specific thing that makes the vendor board usable.

Moderation of individual cases happens in modmail rather than in threads, because a public discussion of one person’s removal is worse for that person than a private one.